Brain tumor drug penetration study halted early
NCT ID NCT04424966
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial aimed to measure how much of the drug infigratinib reaches brain tumor tissue in people with recurrent high-grade glioma (a type of brain cancer). Only 7 participants were enrolled before the study was terminated. The main goal was to check drug levels in the tumor, blood, and spinal fluid after a single dose before surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GBM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chandler Regional Medical Center
Chandler, Arizona, 85224, United States
-
HonorHealth Scottsdale Osborn Medical Center
Scottsdale, Arizona, 85251, United States
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?